Business
Why the Immutep (ASX:IMM) share price will be in focus today
Immutep Ltd (ASX: IMM) shares will be on watch this morning after the company announced it has secured a second United States patent for eftilagimod alpha. The Immutep share price ended Tuesday’s trading session up 8.1% to 33 cents.
Immutep is a global biotech that is focused on developing immunotherapy therapies for cancer and autoimmune diseases. Its lead product, eftilagimod alpha, is a soluble LAG-3Ig fusion protein based on the LAG-3 which is in clinical development.
New patent added
The Immutep share price could be on the move today following the company’s latest update released after yesterday’s market close
According to its…
-
Noosa News23 hours agoOver $50K raised for Noosa’s Oz Bayldon after brain aneurysm
-
General21 hours agoCoalition seeks to rebuild ties with Indian community
-
Business20 hours agoHow to retire in your 50s with ASX shares
-
Noosa News22 hours agoNational Drought Forum convenes in SA to put policy under scrutiny